Masashi Iwabuchi1, Izaya Nakaya2, Yoshinori Tsuchiya1, Yugo Shibagaki3, Takuhiro Yamaguchi4, Shunichi Fukuhara5, Yuji Oe1, Tsutomu Sakuma6, Toshinobu Sato1, Yoshio Taguma1, Jun Soma7. 1. Department of Nephrology, Japan Community Health Care Organization Sendai Hospital, Sendai, Japan. 2. Department of Nephrology, Iwate Prefectural Central Hospital, Ueda 1-4-1, Morioka, 020-0066, Japan. inakaya@chuo-hp.jp. 3. Division of Nephrology and Hypertension, St. Marianna University School of Medical Hospital, Kawasaki, Japan. 4. Department of Biostatistics, Tohoku University School of Medicine, Sendai, Japan. 5. Department of Epidemiology and Healthcare Research, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan. 6. Department of Pathology, Iwate Prefectural Central Hospital, Morioka, Japan. 7. Department of Nephrology, Iwate Prefectural Central Hospital, Ueda 1-4-1, Morioka, 020-0066, Japan.
Abstract
BACKGROUND: The aim of this study was to determine the efficacy of cyclophosphamide (CY) on anti-neutrophil cytoplasmic antibody (ANCA)-positive microscopic polyangiitis (MPA) with renal involvement in Japanese patients. METHODS: Eighty-two patients with newly diagnosed ANCA-positive MPA were enrolled in this retrospective study. Patients were divided into two groups based on whether they received combination therapy with a corticosteroid (CS) plus CY (CY group) or CS alone or with other therapies (non-CY group). The primary outcome was defined as the combination of death and end-stage renal disease (ESRD). RESULTS: The CY and non-CY groups included 29 and 53 patients, respectively. In the non-CY group, 31 patients were treated with CS alone, and 22 with a combination of CS and other therapeutics. The percentage of males and mean Birmingham vasculitis activity scores were higher in the CY group than those in the non-CY group, but other factors such as age, serum creatinine, serum albumin, or CRP at baseline were equivalent in the two groups. No differences were observed in remission rates using induction therapy for the two groups. However, the survival rate 5 years after induction therapy was lower in the CY group than in the non-CY group (0.50 vs. 0.73; P = 0.041), although the hazard ratio of CY for the primary outcome adjusted for all confounding factors was 1.321 [95 % confidence interval (CI), 0.662-2.637; P = 0.171]. CONCLUSIONS: CY may not have an additive effect on induction therapy with CS for Japanese patients with renal vasculitis associated with ANCA-positive MPA.
BACKGROUND: The aim of this study was to determine the efficacy of cyclophosphamide (CY) on anti-neutrophil cytoplasmic antibody (ANCA)-positive microscopic polyangiitis (MPA) with renal involvement in Japanese patients. METHODS: Eighty-two patients with newly diagnosed ANCA-positive MPA were enrolled in this retrospective study. Patients were divided into two groups based on whether they received combination therapy with a corticosteroid (CS) plus CY (CY group) or CS alone or with other therapies (non-CY group). The primary outcome was defined as the combination of death and end-stage renal disease (ESRD). RESULTS: The CY and non-CY groups included 29 and 53 patients, respectively. In the non-CY group, 31 patients were treated with CS alone, and 22 with a combination of CS and other therapeutics. The percentage of males and mean Birmingham vasculitis activity scores were higher in the CY group than those in the non-CY group, but other factors such as age, serum creatinine, serum albumin, or CRP at baseline were equivalent in the two groups. No differences were observed in remission rates using induction therapy for the two groups. However, the survival rate 5 years after induction therapy was lower in the CY group than in the non-CY group (0.50 vs. 0.73; P = 0.041), although the hazard ratio of CY for the primary outcome adjusted for all confounding factors was 1.321 [95 % confidence interval (CI), 0.662-2.637; P = 0.171]. CONCLUSIONS:CY may not have an additive effect on induction therapy with CS for Japanese patients with renal vasculitis associated with ANCA-positive MPA.
Authors: Lorraine Harper; Matthew D Morgan; Michael Walsh; Peter Hoglund; Kerstin Westman; Oliver Flossmann; Vladimir Tesar; Phillipe Vanhille; Kirsten de Groot; Raashid Luqmani; Luis Felipe Flores-Suarez; Richard Watts; Charles Pusey; Annette Bruchfeld; Niels Rasmussen; Daniel Blockmans; Caroline O Savage; David Jayne Journal: Ann Rheum Dis Date: 2011-11-29 Impact factor: 19.103
Authors: Shouichi Fujimoto; Richard A Watts; Shigeto Kobayashi; Kazuo Suzuki; David R W Jayne; David G I Scott; Hiroshi Hashimoto; Hiroyuki Nunoi Journal: Rheumatology (Oxford) Date: 2011-07-28 Impact factor: 7.580
Authors: Richard A Watts; David G I Scott; David R W Jayne; Toshiko Ito-Ihara; Eri Muso; Shouichi Fujimoto; Yasuki Harabuchi; Shigeto Kobayashi; Kazuo Suzuki; Hiroshi Hashimoto Journal: Nephrol Dial Transplant Date: 2008-06-19 Impact factor: 5.992
Authors: J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts Journal: Arthritis Rheum Date: 2013-01